Borderline Resectable Pancreatic Adenocarcinoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

In general, borderline resectable pancreatic cancer is not clear whether it is resectable or not, and rather has a high risk of partial resection if there is previous surgery. Although several tissues have generated classifications, there are still no criteria for what constitutes borderline resectable pancreatic cancer. With approximately 41,780 cancer-related deaths in 2016, pancreatic adenocarcinoma (PDAC) is the third most common cause of cancer death in the United States. It is projected to overtake all other causes as the second leading cause of cancer death by 2030. The diverse clinical findings recognizing the continuum between resectable and unresectable locally advanced disease have led to the recognition of borderline resectable pancreatic cancer as a clinical entity worthy of investigation.

Description

In general, pancreatic cancer that is borderline resectable indicates a higher risk of partial resection in the event of upfront surgery rather than being obviously resectable or unresectable. Although several organizations have published classifications, there is still no agreed-upon definition of what qualifies as borderline resectable pancreatic cancer. The AHPBA/SSAT/SSO/NCCN definition classifies borderline resectable PDAC tumors as having the following features: (1) SMV/PV venous involvement with tumor abutment, encasement, or short segment venous occlusion, but with suitable vessels proximal and distal to the area of vessel involvement, allowing for safe resection and reconstruction; (2) Encasement of the gastroduodenal artery up to the hepatic. Pancreatic tumors are surrounded by a thick tissue layer known as the stroma, which makes it difficult for therapy to reach the tumor, claims the Pancreatic Cancer Action Network. Researchers are looking for approaches to deliver therapy through the stroma to increase its efficacy.

Borderline Resectable Pancreatic Adenocarcinoma (Epidemiology)

Pancreatic ductal adenocarcinoma (PDAC), estimated to have caused 41,780 deaths from cancer-related causes in 2016, is the third most common cancer-related cause of mortality in the United States. It is anticipated that it will surpass other causes to become the second-most common cause of cancer death by the year 2030. Nearly 80% of PDAC patients have metastatic or incurable disease at the time of diagnosis, which is typical for this aggressive and treatment-resistant cancer. The BRPC, which is emerging as a distinct clinical entity with increasing clinical recognition, is characterized by an initial tumor that affects the surrounding vasculature and a high risk for margin-positive resection if it is resected de novo or surgically removed in patients who have just been diagnosed.

Borderline Resectable Pancreatic Adenocarcinoma -Current Market Size & Forecast Trends

The market for borderline resectable pancreatic adenocarcinoma is expected to grow significantly, with the global pancreatic cancer treatment market estimated at USD 2.92 billion in 2024 and projected to reach USD 5.84 billion by 2030, reflecting a CAGR of approximately 12.30% from 2025 to 2030. This growth is driven by rising incidence rates of pancreatic cancer, advancements in diagnostic techniques, and the increasing adoption of neoadjuvant therapies aimed at improving surgical outcomes for borderline resectable cases. As the understanding of this complex disease evolves, there is a growing emphasis on multimodal treatment approaches and personalized medicine, which are likely to further enhance market dynamics. Additionally, the aging population and lifestyle-related risk factors contribute to a higher demand for effective treatment options, positioning the market for continued expansion through 2035.

The recognition of borderline resectable pancreatic cancer as a clinical entity deserving of research has been influenced by a number of clinical findings that acknowledge a continuum between resectable and locally advanced unresectable diseases. There aren't enough prospective studies available for borderline resectable PDAC, so there isn't enough evidence to support any particular neoadjuvant treatment plan. According to several studies, the results of R0 resection in patients with PDAC who are borderline resectable and receive neoadjuvant therapy, according to several studies, are comparable to those of patients with a disease that is initially resectable. More funding and research will help pharmaceutical companies compete in the upcoming market because Borderline Resectable Pancreatic Adenocarcinoma represents a lucrative opportunity. Many pharmaceutical companies will create innovative therapies as a result of the lack of a comprehensive understanding of the illness. IMC-CS4 (ImClone Systems), BMS-813160 (Bristol-Myers Squibb), Irinotecan sucrosofate (Ipsen), and other businesses have begun their clinical trials to seize this lucrative market.

Report Highlights

Borderline Resectable Pancreatic Adenocarcinoma - Current Market Trends

Borderline Resectable Pancreatic Adenocarcinoma - Current & Forecasted Cases across the G8 Countries

Borderline Resectable Pancreatic Adenocarcinoma - Market Opportunities and Sales Potential for Agents

Borderline Resectable Pancreatic Adenocarcinoma - Patient-based Market Forecast to 2035

Borderline Resectable Pancreatic Adenocarcinoma - Untapped Business Opportunities

Borderline Resectable Pancreatic Adenocarcinoma - Product Positioning Vis-a-vis Competitors' Products

Borderline Resectable Pancreatic Adenocarcinoma - KOLs Insight